Philadelphia, PA – Chimeron Bio, a next generation RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary Multiplex delivery platform, announced today that the company has been recognized by MilliporeSigma as a finalist in the company’s North American Advance Biotech Grant. As part of the award, Chimeron will receive in-kind products and services from MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.
“Being recognized as a finalist in MilliporeSigma’s Advance Biotech Grant is an honor,” said Kevin Heyeck, CEO of Chimeron Bio. “It recognizes the unique innovation of our platform and the support from the MilliporeSigma team will help us expedite our work and further scale solutions for next-generation RNA therapeutics.”
Since 2014, the Life Science business sector’s Advance Biotech Grant program has awarded technologies and consultation to nearly 40 biotechnology companies around the world, supporting their efforts to improve patient outcomes for various diseases such as cancer, brain tumors, osteoarthritis, and cardiovascular disorders. The company is set to award its next grant in the APAC region in July, further expanding its commitment to supporting emerging biotech companies worldwide.
About Chimeron Bio
Chimeron Bio is a biotechnology company dedicated to advancing genetic medicine through the development and delivery of next generation RNA therapeutics. Chimeron employs an innovative combination of its proprietary multiplex delivery vector and self-amplified RNA (saRNA) technology to create and deliver therapeutics with the potential for meaningful patient results. The company is developing a high-impact pipeline across a range of conditions including oncology, genetic disorders, and infectious diseases. For more information, visit www.chimeron.com.
